A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

May 12, 2025

Study Completion Date

May 12, 2025

Conditions

Healthy Participants

Interventions

DRUG

Rozanolixizumab

Dose formulation: Solution for injection Route of administration: Subcutaneous infusion

Trial Locations (2)

UP0141 2, San Antonio

UP0141 1, Salt Lake City

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY

NCT06720714 - A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women | Biotech Hunter | Biotech Hunter